

Multiple myeloma (MM) is a type of blood cancer that arises from plasma cells, a type of white blood cell responsible for fighting infections. In multiple myeloma, abnormal plasma cells accumulate in the bone marrow and produce proteins called M-proteins, which can disrupt normal blood and organ function. Common symptoms include bone pain, weakness, fatigue, weight loss, poor appetite, nausea, and constipation. Risk factors include increasing age, male gender, family history, and a history of monoclonal gammopathy of undetermined significance (MGUS).
The Multiple Myeloma Comprehensive Panel Quantitative, Serum includes several tests including Serum Protein Electrophoresis (SPEP), Serum Immunotyping, Immunoglobulin Profile (IgG, IgA, IgM), Kappa and Lambda Freelite assay, and Beta-2 Microglobulin. Serum Protein Electrophoresis (SPEP) detects and quantifies abnormal monoclonal (M) proteins in the blood. Serum Immunotyping confirms the presence and identifies the type of monoclonal immunoglobulin. Immunoglobulin Profile (IgG, IgA, and IgM) measures the levels of the major antibody classes and helps identify monoclonal protein production or suppression of normal immunoglobulins. Serum Free Light Chain (Kappa and Lambda Freelite®) Assay measures circulating free light chains and their ratio, aiding in the diagnosis and monitoring of light chain myeloma, AL amyloidosis, and other plasma cell disorders. Beta-2 Microglobulin is a marker of tumor burden and kidney function and is widely used to assess disease severity and prognosis in multiple myeloma.
This comprehensive panel enables doctors to detect multiple myeloma early, classify disease stage, monitor response to therapy, and identify patients at higher risk of aggressive disease. By providing a detailed molecular and protein profile, this test supports personalized treatment planning and effective disease management.
Doctors may recommend this test for patients who present with symptoms like bone pain, fatigue, anemia, or abnormal kidney function, or for those who need monitoring after a previous diagnosis of multiple myeloma or related plasma cell disorders.
For this test, it is important to submit the clinical history, histopathology report, previous test results, and a doctor’s prescription at the time of sample collection. The Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled and submitted.
Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for proper understanding of the test results.
The Multiple Myeloma Comprehensive Panel Quantitative, Serum measures abnormal proteins and biomarkers produced by malignant plasma cells including.
- Serum Protein Electrophoresis (SPEP) detects and quantifies abnormal monoclonal (M) proteins in the blood.
- Serum Immunotyping confirms the presence and identifies the type of monoclonal immunoglobulin.
- Immunoglobulin Profile (IgG, IgA, IgM): Evaluates the levels of major immunoglobulins.
- Kappa and Lambda Freelite Assay: Measures free Kappa and Lambda light chains in the blood to detect abnormal production by plasma cells and support the diagnosis and monitoring of multiple myeloma.
- Beta-2 Microglobulin: Acts as a marker of disease burden and prognosis.
By combining these tests, doctors can identify monoclonal proteins, evaluate antibody production, assess disease burden, detect abnormal free light chain production, monitor disease activity, and make informed treatment decisions. This comprehensive panel supports accurate diagnosis, prognosis, and personalized management of multiple myeloma and related plasma cell disorders.
The Protein Electrophoresis, Serum test measures the concentration and distribution of specific proteins (like albumin, alpha globulins, beta globulins, and gamma globulins) in the blood. Each of these plays a vital role in bodily functions. This test aids in the detection of abnormal proteins, particularly monoclonal (M) proteins. The presence of M proteins may indicate plasma cell disorders such as multiple myeloma (a blood cancer that affects plasma cells in the bone marrow). Also, this test helps diagnose and monitor various blood disorders.
Know more about Protein Electrophoresis, Serum
The Immunoglobulin G test measures the concentration of IgG antibodies present in the serum. These antibodies are produced by the immune system in response to specific pathogens or infections. Elevated levels of IgG can indicate recent or chronic infections, while lower levels may suggest an impaired immune response or deficiency. This test is crucial for assessing an individual’s immune status and provides valuable information for doctors to make informed clinical decisions regarding diagnosis, treatment strategies, and ongoing management of various health conditions.
Know more about Immunoglobulin G
The Multiple Myeloma Comprehensive Panel Quantitative, Serum is done:
- To help diagnose new cases of multiple myeloma or related plasma cell disorders.
- To monitor disease progression or treatment response in patients diagnosed with multiple myeloma.
- To assess prognosis using markers like Beta-2 Microglobulin.
- To evaluate abnormal protein levels detected in routine blood tests.
- To identify patients at higher risk for aggressive disease and guide personalized treatment decisions.
- Provide your clinical history, previous test reports, and a valid prescription. Tata 1mg consolidated TRF to be filled.























